Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

PHASE4CompletedINTERVENTIONAL
Enrollment

1,439

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
MumpsRubellaMeaslesVaricella
Interventions
BIOLOGICAL

Measles, Mumps, Rubella and Chickenpox (live vaccine)

Trial Locations (54)

11527

GSK Investigational Site, Athens

15140

GSK Investigational Site, Lahti

20520

GSK Investigational Site, Turku

28120

GSK Investigational Site, Pori

32278

GSK Investigational Site, Kirchlengern

32339

GSK Investigational Site, Espelkamp

32427

GSK Investigational Site, Minden

32479

GSK Investigational Site, Hille

32549

GSK Investigational Site, Bad Oeynhausen

32584

GSK Investigational Site, Löhne

32756

GSK Investigational Site, Detmold

33200

GSK Investigational Site, Tampere

33332

GSK Investigational Site, Gütersloh

36037

GSK Investigational Site, Fulda

37269

GSK Investigational Site, Eschwege

38226

GSK Investigational Site, Salzgitter

38302

GSK Investigational Site, Wolfenbüttel

41061

GSK Investigational Site, Mönchengladbach

41236

GSK Investigational Site, Mönchengladbach

44329

GSK Investigational Site, Dortmund

44866

GSK Investigational Site, Bochum

47574

GSK Investigational Site, Goch

47798

GSK Investigational Site, Krefeld

47877

GSK Investigational Site, Willich

48159

GSK Investigational Site, Münster

50389

GSK Investigational Site, Wesseling

54636

GSK Investigational Site, Thessaloniki

60389

GSK Investigational Site, Frankfurt am Main

61130

GSK Investigational Site, Nidderau

65205

GSK Investigational Site, Wiesbaden

69100

GSK Investigational Site, Komotini

81241

GSK Investigational Site, Munich

81735

GSK Investigational Site, Munich

82140

GSK Investigational Site, Olching

82327

GSK Investigational Site, Tutzing

83684

GSK Investigational Site, Tegernsee

86399

GSK Investigational Site, Bobingen

86720

GSK Investigational Site, Nördlingen

87435

GSK Investigational Site, Kempten (Allgäu)

90100

GSK Investigational Site, Oulu

90473

GSK Investigational Site, Nuremberg

93413

GSK Investigational Site, Cham

95444

GSK Investigational Site, Bayreuth

95463

GSK Investigational Site, Bindlach

97209

GSK Investigational Site, Veitshöchheim

02100

GSK Investigational Site, Espoo

01300

GSK Investigational Site, Vantaa

471 00

GSK Investigational Site, Arta

851 00

GSK Investigational Site, Rhodes

85-021

GSK Investigational Site, Bydgoszcz

31-202

GSK Investigational Site, Krakow

61-709

GSK Investigational Site, Poznan

41-103

GSK Investigational Site, Siemianowice Śląskie

55-100

GSK Investigational Site, Trzebnica

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY